Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2011

View Archived Issues

New carbapenem antibiotics described

Irosustat demonstrates pharmacodynamic proof of concept

New DNA vaccine is efficacious in monkey model of tuberculosis

Gantenerumab reduces amyloid levels in brain

Scientists in U.K. identify microRNA biomarker in COPD

Phase I/II data disclosed on trabedersen in melanoma, pancreatic and colorectal carcinoma

Intellikine advances first-in-human trial of INK-1117

Ironwood Pharmaceuticals prepares new GCS activators

Isis Pharmaceuticals selects second development candidate in GlaxoSmithKline collaboration

Dainippon Sumitomo Pharma discloses novel agents for sepsis

ISCO reports promising preclinical results with hpSC-derived neuronal cells

New deuterated dimethylcurcumin derivatives claimed by Concert Pharmaceuticals

Scientists at Gilead Sciences patent new SYK inhibitors

Novel histamine receptor antagonists presented by Kalypsys

Medicago completes first stage of noninfluenza VLP vaccine collaboration agreement

Michael J. Fox Foundation funds clinical study of Parkinson's disease vaccine

ISTA provides update on development of bromfenac ophthalmic solutions

Topline data reported from Pozen's phase III PA-32540 study

FDA grants pre-IND meeting to Advaxis for ADXS-HER2

DSMB recommends continuing Cyclacel's SEAMLESS trial

Micromet outlines registration strategy for blinatumomab

Kissei Pharmaceutical to pay MediciNova for further development of MN-221

Baxter International starts phase III trial of recombinant von Willebrand factor

FDA committee recommends approval of Zilver PTX paclitaxel-eluting stent

Telik commences phase IIb trial of Telintra

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...